Retrospective analysis evaluating ovarian cancer cases presented at the clinical oncology department, Alexandria University

Available online 9 August 2012

Peer review under the responsibility of Alexandria University Faculty of Medicine.

Figures & data

Table 1 Clinico-pathologic criteria in the studied patients.

Age	Number	Percentage
Mean age all patients	47.9 years ± 13.9	–
Mean age EOC	48.5 years ± 12.7	–
Positive Family history	16	13.7
Histopathology
EOC:	87	75
Border line tumors:	15	12.9
Granulosa cell tumors:	7	6
Germ cell tumors:	5	4.3
Krukenberg tumors	2	1.7
Total number of cases in the study	116	100
Grade of the tumor (all patients)
GI	11	9.4
GII	37	31.8
GIII	53	45.6
Duration of symptoms
Maximum:	18 months	–
Minimum:	2 months	–
Mean:	6 ± 2.8 months	–
Common symptoms
Abdominal discomfort	109	93.9
Abdominal distention	104	89.6
Menstrual irregularities	63	54.3
Pelvic pain	31	26.7
Constipation	11	9.4
Dyspnea	5	4.3
Intermittent intestinal obstruction	3	2.5
Elevated CA 125 level for EOC	87	100

EOC; epithelial ovarian cancer.

Table 2 Stage information in the studied patients.

Stage	EOC (%)	Border lie tumors (%)	Granulosa cell tumors (%)	Germ cell tumors (%)
I	6.8	86.6	28.5	40
II	8.2		–	–
III	50.6	13.3	28.5	–
IV	34.4	–	42.8	60

Table 3 Summary of surgery in the studied patients.

Surgery as a treatment modality for the whole studied patients:	Number of patients	Percentage
Patients started initial surgery	94^*	81
Patients underwent surgery after neo-adjuvant chemotherapy	8	6.8
Total patients received surgery during treatment.	102/116	87.9
Type of surgery
EOC	70/87	80.4
TAH & BSO	59/70	84.2
Debulking	9/70	12.8
Unilateral oophorectomy	2/70	2.8
No residual or residual < 2 cm	24/70	34.2
Residual > 2 cm	46/70	65.8
Border line tumors
Unilateral oophorectomy	13/15	86.6
TAH & BSO	1/15	6.6
Debulking	2/15	13
Sex cord tumors
TAH & BSO	3/7	42.8
Unilateral oophorectomy	2/7	28.5
Germ cell tumor
Unilateral oophorectomy	2/5	40

* the number includes the two patients with krukenberg metastasis.

Table 4 Type of chemotherapy regimens used in different lines of treatment for EOC.

Chemotherapy used for EOC^*	Number of patients	Percentage
First line
Did not receive adjuvant chemotherapy	3	3.4
Carboplatin–adriamycin–cyclophosphamide (CAP)	6	6.8
Carboplatin	21	24.1
Carboplatin–cyclophosphamide	1	1.1
Paclitaxel–carboplatin	56	64.3
Second line
Gemcitabine- carboplatin	17	47.2
Paclitaxel- carboplatin	15	41.6
Gemcitabine	2	5.5
Oral etoposide	2	5.5
Third line
Paclitaxel- carboplatin	2	14.2
Liposomal doxorubicin	3	21.4
Gemcitabine	1	7.1
Tamoxifen	7	50
Etoposide	1	7.1

* Epithelial ovarian carcinoma.

Table 5 The response rate after different chemotherapy lines in epithelial ovarian cancer.

	CR (%)	PR (%)	SD (%)	PD (%)
Response rate to first line chemotherapy	44.8	42.5	6.8	5.7
Response rate to second line chemotherapy	27.7	41.6	22.2	8.3
Response rate to third line chemotherapy	–	–	50	50